Virbac Financial Statements From 2010 to 2025
| VRBCF Stock | USD 346.00 85.80 19.87% |
Check Virbac SA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virbac SA's main balance sheet or income statement drivers, such as , as well as many indicators such as . Virbac financial statements analysis is a perfect complement when working with Virbac SA Valuation or Volatility modules.
Virbac |
Virbac SA Company Return On Equity Analysis
Virbac SA's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Virbac SA Return On Equity | 0.15 |
Most of Virbac SA's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Virbac SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Virbac SA has a Return On Equity of 0.1542. This is 100.64% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The return on equity for all United States stocks is 149.74% lower than that of the firm.
Virbac SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Virbac SA's current stock value. Our valuation model uses many indicators to compare Virbac SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Virbac SA competition to find correlations between indicators driving Virbac SA's intrinsic value. More Info.Virbac SA is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.59 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Virbac SA is roughly 1.69 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Virbac SA's earnings, one of the primary drivers of an investment's value.About Virbac SA Financial Statements
Virbac SA stakeholders use historical fundamental indicators, such as Virbac SA's revenue or net income, to determine how well the company is positioned to perform in the future. Although Virbac SA investors may analyze each financial statement separately, they are all interrelated. For example, changes in Virbac SA's assets and liabilities are reflected in the revenues and expenses on Virbac SA's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Virbac SA. Please read more on our technical analysis and fundamental analysis pages.
Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa. Virbac SA was founded in 1968 and is headquartered in Carros, France. Virbac Sa operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 5120 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Virbac Pink Sheet
Virbac SA financial ratios help investors to determine whether Virbac Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Virbac with respect to the benefits of owning Virbac SA security.